-
VolitionRx reports feline cancer test detects 80% of lymphomas
-
VolitionRx receives first clinical order for cancer test
-
VolitionRx sells first Nu.Q cancer assays to French hospital
-
VolitionRX (VNRX) PT Lowered to $1 at Freedom Capital Markets
-
VolitionRX (VNRX) PT Lowered to $1.50 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on VolitionRX (VNRX)
-
VolitionRx signs co-marketing deal with Hologic for discovery service
-
Benchmark Reiterates Hold Rating on VolitionRX (VNRX)
-
H.C. Wainwright Reiterates Buy Rating on VolitionRX (VNRX)
-
VolitionRx signs licensing deal with Werfen for blood clot test
-
Volitionrx Limited (VNRX) Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
-
Jones Trading Starts VolitionRX (VNRX) at Buy
-
Benchmark Reiterates Hold Rating on VolitionRX (VNRX)
-
Volitionrx Limited (VNRX) Misses Q1 EPS by 2c
-
H.C. Wainwright Reiterates Buy Rating on VolitionRX (VNRX)
-
Benchmark Reiterates Hold Rating on VolitionRX (VNRX)
-
Volitionrx Limited (VNRX) Prices $2.3M Share Offering
-
Volitionrx (VNRX) says study shows Nu.Q Cancer immunoassay test in development detected a range of 21 different cancers
-
Volitionrx Limited (VNRX) Signs first ever Nu.Q Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
-
Volitionrx Limited (VNRX) Issues Business Review 2024
-
Volitionrx Limited (VNRX) Issues Business Review 2024
-
Volitionrx Limited (VNRX) Announces Pricing of up to $1.9 Million Registered Direct Offering
-
Volitionrx Limited (VNRX) Appoints Ethel Rubin to its Board
-
Volitionrx Limited (VNRX) Prices $21.5M Share and Warrant Offering

